Oncopepeptides has decided to reduce the activity level in the clinical development program with melflufen (INN melphalan flufenamide) to increase the company's cash runway and at the same time support the ongoing marketing authorization application process in Europe.
- OCEAN study will continue with long-term follow-up and documentation in accordance to previous plans.
- Patient recruitment has been completed in both PORT and BRIDGE and the studies can be closed with relevant scientific data sets.
- ANCHOR will close without the last 10 previously planned patients in the bortezomib + melflufen study arm – data sets will be large enough to draw relevant scientific conclusions.
- ASCENT, COAST and LIGHTHOUSE will close with incomplete number of patients, it will not be possible to draw any relevant scientific conclusions from these data sets.
Read the press release - Oncopeptides focuses clinical development efforts to increase cash runway
Investigators and Patients should be aware that there is a partial clinical hold in place for Oncopeptides’ Clinical Trials, which means that we are not currently enrolling new patients. If patients are receiving a clinical benefit from melphalan flufenamide they may continue treatment provided they are informed of the risks and sign a revised written informed consent.